Download

Download Full Text (560 KB)

Contents

  • New Drug Control Symptoms of Myeloproliferative Disorders and Improve Quality of Life for Patients: Recent clinical trials have demonstrated that a new class of drugs can effectively treat myeloproliferative disorders
  • Compass: Metastatic Melanoma: Experimental treatments could be preferable to standard therapies for metastatic melanoma
  • HOUS CALL: Breast Awareness: Guidelines recommend breast awareness rather than formal self-exams

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Publication Date

1-2011

Publisher

The University of Texas MD Anderson Cancer Center

City

Houston, Texas

Keywords

Verstovek, Srdan; Woodman, Scott; Kim, Kevin; Davies, Michael; Hwu, Patrick; Myeloproliferative Disorders; Philadelphia Chromosome; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polycythemia Vera; Thrombocythemia, Essential; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocytosis; Hypereosinophilic Syndrome; Mastocytosis, Systemic; Prednisone; Hydroxyurea; Imatinib Mesylate; Dasatinib; Pyrimidines; Janus Kinase 2; ruxolitinib; Melanoma; Melanoma -- secondary; Antineoplastic Agents; Dacarbazine; Drug Resistance, Neoplasm; Interleukin-2; Interferon alpha-2; BRAF protein, human; Vemurafenib; Ipilimumab; Antibodies, Monoclonal; Cancer Vaccines; Immunotherapy, Adoptive; Health Knowledge, Attitudes, Practice; Breast Self-Examination.

Disciplines

History of Science, Technology, and Medicine | Oncology

Conditions Governing Access

Redacted

OncoLog, Volume 56, Number 01, January 2011

Share

COinS